All In Biotech

Drug Trial Radar · NCT07399171

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

May 12, 2026

Primary completion

Feb 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Halia Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau related blood biomarker progression over the study period. * To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period. * To assess the safety and tolerability of HT-4253 in the UAE population.

Conditions

  • Alzheimers Disease

Interventions

  • HT-4253Drug

    It is anticipated that 112 participants will be randomized to receive HT-4253 (56 in each study arm).

  • PlaceboOther

    It is anticipated that 112 participants will be randomized to receive placebo (56 in each study arm).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: 48 weeks
  2. Primary EndpointTime frame: Week 48
  3. Primary EndpointTime frame: Week 48
  4. Primary EndpointTime frame: Week 48

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic Abu Dhabi

    Abu Dhabi, United Arab Emirates · Not yet recruiting

  • Burjeel Medical City

    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · Recruiting

  • Sheikh Shakbout Medical City (SSMC)

    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.